Non-Invasive Industry ($OCX, $NAOV, $ECOR...)Stocks: A Spotlight on the 14.4% Average Weekly Gain
The non-invasive sector encompasses manufacturers dedicated to the development of noninvasive biological response-activating devices. Companies like NanoVibronix Inc. are at the forefront, innovating medical products using low-intensity acoustic technology. Meanwhile, OncoCyte Corp. specializes in non-invasive, liquid biopsy diagnostics, paving the way for early cancer detection. Neuronetics Inc. stands out with its non-invasive therapeutic solutions targeting psychiatric and neurological disorders.
Tickers in Industry - $OCX, $NAOV, $ECOR, $STIM, $ANIX
Notable Companies
- NanoVibronix Inc.
- OncoCyte Corp.
- Neuronetics Inc.
Market Capitalization
Within the non-invasive theme, the average market capitalization stands at $45.3M. Valuations among these tickers vary, ranging from a modest $4.3M to a more substantial $112.8M. Anixa Biosciences (ANIX) takes the lead with the highest valuation at $112.8M, while NanoVibronix (NAOV) sits at the lower end with a valuation of $4.3M.
Price Movements: Highs and Lows
The non-invasive sector witnessed an impressive average weekly growth of 14.4%. However, on a broader scale, the monthly and quarterly growth rates were -2.1% and -22.87%, respectively. NanoVibronix (NAOV) emerged as the star performer with a staggering price growth of 49.71%. In contrast, Anixa Biosciences (ANIX) saw a minimal decline of 1.11%.
Key Price Movements:
- electroCore (ECOR, $5.08) faced a significant weekly decline of -15.89% as of 8/16/23.
- electroCore (ECOR, $4.68) enjoyed a weekly gain of +15.84% as of 6/30/23.
- Oncocyte (OCX, $0.22) registered a weekly drop of -17.33% as of 5/24/23.
Volume Analysis
The non-invasive sector experienced a remarkable average weekly volume growth of 639.65%. This trend extends to the monthly timeframe, with a growth of 226.76%, and a quarterly growth of 35.2%.
Noteworthy Volume Movements:
- Neuronetics stock saw a record-breaking daily volume growth of 280% of the 65-Day Volume Moving Average on 8/15/23.
- Anixa Biosciences stock experienced a significant daily volume growth of 586% of the 65-Day Volume Moving Average on 7/12/23.
- Oncocyte stock registered a daily volume growth of 437% of the 65-Day Volume Moving Average on 4/11/23.
Fundamental Analysis Ratings
The fundamental analysis ratings provide insights into the industry's health and potential. While specific ratings were not provided, it's essential to note that a rating closer to 1 indicates a more favorable outlook, while a rating closer to 100 suggests challenges or concerns.
In conclusion, the non-invasive sector's recent performance, especially the 14.4% average weekly gain, highlights its potential and the innovative strides being made by companies within this theme.
OCX - On August 25, 2023, OCX's Aroon Indicator showcased a bearish trend. Tickeron's A.I.dvisor detected a scenario where the AroonDown line surpassed 70, while the AroonUp line lingered below 30 for three consecutive days. Historically, such a pattern often precedes a significant decline in the stock. Investors might consider offloading their shares or exploring put options. Past data reveals that in 249 out of 264 instances where OCX exhibited this pattern, the stock trended downwards, suggesting a 90% probability of a similar outcome this time.
STIM - As of August 23, 2023, STIM has registered a -2.44% decline, marking its third consecutive day of descent. Historically, such a three-day downward trajectory often signals further potential drops. Analyzing past patterns, in 297 out of 325 instances where STIM faced a similar three-day decline, the stock continued its downward trend in the subsequent month. This indicates a 90% likelihood of the trend persisting. Investors should monitor STIM closely in the coming weeks.
ANIX - On August 7, 2023, ANIX's Moving Average Convergence Divergence (MACD) Histogram shifted into negative territory, signaling potential bearish momentum for the stock. Historical analysis by Tickeron's A.I.dvisor reveals that in 40 out of 44 previous occurrences where the MACD turned negative, ANIX experienced a subsequent decline. This suggests a 90% probability of the stock continuing its downward trajectory in the upcoming days. Investors should remain vigilant.
IMDX sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for IMDX moved above the 200-day moving average on October 07, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2025. You may want to consider a long position or call options on IMDX as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IMDX just turned positive on October 07, 2025. Looking at past instances where IMDX's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
IMDX moved above its 50-day moving average on September 10, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IMDX crossed bullishly above the 50-day moving average on September 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMDX advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 88 cases where IMDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IMDX broke above its upper Bollinger Band on October 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: IMDX's P/B Ratio (102.041) is very high in comparison to the industry average of (11.821). P/E Ratio (0.000) is within average values for comparable stocks, (140.008). IMDX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.756). IMDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (20.367) is also within normal values, averaging (9.045).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of ovel, non-invasive, liquid biopsy diagnostics for the early detection of cancer
Industry MedicalSpecialties
Advertisement